An evaluation of sacituzumab tirumotecan for the treatment of NSCLC.
INTRODUCTION Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, and resistance to targeted therapy and immunotherapy represents a substantial unmet clinical need. Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) have emerged as a promising therapeu...